This unique group of patients are presently labelled as ‘primary Epstein-Barr virus (EBV)-positive nodal T/NK-cell lymphoma’ (PTCL-EBV) and were identified via clinicopathological features such as the primary presentation of nodal disease where the bulk of tumor is localized, lack of nasal involvement, and/or expression of a CD8+/CD56– phenotype. This evidence concerns the gene NCAM1 and extranodal nasal NK/T cell lymphoma.